Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 May;39(5):1201–1203. doi: 10.1128/aac.39.5.1201

Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii.

J Vila 1, J Ruiz 1, P Goñi 1, A Marcos 1, T Jimenez de Anta 1
PMCID: PMC162713  PMID: 7625818

Abstract

The gyrA gene mutations associated with quinolone resistance were determined in 21 epidemiologically unrelated clinical isolates of Acinetobacter baumannii. Our studies highlight the conserved sequences in the quinolone resistance-determining region of the gyrA gene from A. baumannii and other bacteria. All 15 isolates for which the MIC of ciprofloxacin is > or = 4 micrograms/ml showed a change at Ser-83 to Leu. Six strains for which the MIC of ciprofloxacin is 1 microgram/ml did not show any change at Ser-83, although a strain for which the MIC of ciprofloxacin is 1 microgram/ml exhibited a change at Gly-81 to Val. Although it is possible that mutations in other locations of the gyrA gene, the gyrB gene, or in other genes may also contribute to the modulation of the MIC level, our results suggest that a gyrA mutation at Ser-83 is associated with quinolone resistance in A. baumannii.

Full Text

The Full Text of this article is available as a PDF (200.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acar J. F., O'Brien T. F., Goldstein F. W., Jones R. N. The epidemiology of bacterial resistance to quinolones. Drugs. 1993;45 (Suppl 3):24–28. doi: 10.2165/00003495-199300453-00006. [DOI] [PubMed] [Google Scholar]
  2. Beck-Sagué C. M., Jarvis W. R., Brook J. H., Culver D. H., Potts A., Gay E., Shotts B. W., Hill B., Anderson R. L., Weinstein M. P. Epidemic bacteremia due to Acinetobacter baumannii in five intensive care units. Am J Epidemiol. 1990 Oct;132(4):723–733. doi: 10.1093/oxfordjournals.aje.a115714. [DOI] [PubMed] [Google Scholar]
  3. Bergogne-Berezin E., Joly-Guillou M. L. An underestimated nosocomial pathogen, Acinetobacter calcoaceticus. J Antimicrob Chemother. 1985 Nov;16(5):535–538. doi: 10.1093/jac/16.5.535. [DOI] [PubMed] [Google Scholar]
  4. Bergogne-Bérézin E., Joly-Guillou M. L., Vieu J. F. Epidemiology of nosocomial infections due to Acinetobacter calcoaceticus. J Hosp Infect. 1987 Sep;10(2):105–113. doi: 10.1016/0195-6701(87)90135-6. [DOI] [PubMed] [Google Scholar]
  5. Cambau E., Bordon F., Collatz E., Gutmann L. Novel gyrA point mutation in a strain of Escherichia coli resistant to fluoroquinolones but not to nalidixic acid. Antimicrob Agents Chemother. 1993 Jun;37(6):1247–1252. doi: 10.1128/aac.37.6.1247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cefai C., Richards J., Gould F. K., McPeake P. An outbreak of Acinetobacter respiratory tract infection resulting from incomplete disinfection of ventilatory equipment. J Hosp Infect. 1990 Feb;15(2):177–182. doi: 10.1016/0195-6701(90)90128-b. [DOI] [PubMed] [Google Scholar]
  7. Cohen S. P., Hooper D. C., Wolfson J. S., Souza K. S., McMurry L. M., Levy S. B. Endogenous active efflux of norfloxacin in susceptible Escherichia coli. Antimicrob Agents Chemother. 1988 Aug;32(8):1187–1191. doi: 10.1128/aac.32.8.1187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cohen S. P., McMurry L. M., Hooper D. C., Wolfson J. S., Levy S. B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction. Antimicrob Agents Chemother. 1989 Aug;33(8):1318–1325. doi: 10.1128/aac.33.8.1318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. French G. L., Casewell M. W., Roncoroni A. J., Knight S., Phillips I. A hospital outbreak of antibiotic-resistant Acinetobacter anitratus: epidemiology and control. J Hosp Infect. 1980 Jun;1(2):125–131. doi: 10.1016/0195-6701(80)90044-4. [DOI] [PubMed] [Google Scholar]
  10. Goswitz J. J., Willard K. E., Fasching C. E., Peterson L. R. Detection of gyrA gene mutations associated with ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: analysis by polymerase chain reaction and automated direct DNA sequencing. Antimicrob Agents Chemother. 1992 May;36(5):1166–1169. doi: 10.1128/aac.36.5.1166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hartstein A. I., Rashad A. L., Liebler J. M., Actis L. A., Freeman J., Rourke J. W., Jr, Stibolt T. B., Tolmasky M. E., Ellis G. R., Crosa J. H. Multiple intensive care unit outbreak of Acinetobacter calcoaceticus subspecies anitratus respiratory infection and colonization associated with contaminated, reusable ventilator circuits and resuscitation bags. Am J Med. 1988 Nov;85(5):624–631. doi: 10.1016/s0002-9343(88)80233-x. [DOI] [PubMed] [Google Scholar]
  12. Heisig P., Schedletzky H., Falkenstein-Paul H. Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli. Antimicrob Agents Chemother. 1993 Apr;37(4):696–701. doi: 10.1128/aac.37.4.696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hirai K., Aoyama H., Irikura T., Iyobe S., Mitsuhashi S. Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli. Antimicrob Agents Chemother. 1986 Mar;29(3):535–538. doi: 10.1128/aac.29.3.535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Holton J. A report of a further hospital outbreak caused by a multi-resistant Acinetobacter anitratus. J Hosp Infect. 1982 Sep;3(3):305–309. doi: 10.1016/0195-6701(82)90051-2. [DOI] [PubMed] [Google Scholar]
  15. Hooper D. C., Wolfson J. S., Bozza M. A., Ng E. Y. Genetics and regulation of outer membrane protein expression by quinolone resistance loci nfxB, nfxC, and cfxB. Antimicrob Agents Chemother. 1992 May;36(5):1151–1154. doi: 10.1128/aac.36.5.1151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Ishii H., Sato K., Hoshino K., Sato M., Yamaguchi A., Sawai T., Osada Y. Active efflux of ofloxacin by a highly quinolone-resistant strain of Proteus vulgaris. J Antimicrob Chemother. 1991 Dec;28(6):827–836. doi: 10.1093/jac/28.6.827. [DOI] [PubMed] [Google Scholar]
  17. Ito H., Yoshida H., Bogaki-Shonai M., Niga T., Hattori H., Nakamura S. Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob Agents Chemother. 1994 Sep;38(9):2014–2023. doi: 10.1128/aac.38.9.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. King A., Phillips I. The comparative in-vitro activity of eight newer quinolones and nalidixic acid. J Antimicrob Chemother. 1986 Nov;18 (Suppl 500):1–20. doi: 10.1093/jac/18.supplement_d.1. [DOI] [PubMed] [Google Scholar]
  19. Kureishi A., Diver J. M., Beckthold B., Schollaardt T., Bryan L. E. Cloning and nucleotide sequence of Pseudomonas aeruginosa DNA gyrase gyrA gene from strain PAO1 and quinolone-resistant clinical isolates. Antimicrob Agents Chemother. 1994 Sep;38(9):1944–1952. doi: 10.1128/aac.38.9.1944. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Marcos M. A., Abdalla S., Pedraza F., Andreu A., Fernandez F., Gomez-Lus R., Jimenez de Anta M. T., Vila J. Epidemiological markers of Acinetobacter baumannii clinical isolates from a spinal cord injury unit. J Hosp Infect. 1994 Sep;28(1):39–48. doi: 10.1016/0195-6701(94)90151-1. [DOI] [PubMed] [Google Scholar]
  21. Margerrison E. E., Hopewell R., Fisher L. M. Nucleotide sequence of the Staphylococcus aureus gyrB-gyrA locus encoding the DNA gyrase A and B proteins. J Bacteriol. 1992 Mar;174(5):1596–1603. doi: 10.1128/jb.174.5.1596-1603.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Masecar B. L., Celesk R. A., Robillard N. J. Analysis of acquired ciprofloxacin resistance in a clinical strain of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1990 Feb;34(2):281–286. doi: 10.1128/aac.34.2.281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Oram M., Fisher L. M. 4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction. Antimicrob Agents Chemother. 1991 Feb;35(2):387–389. doi: 10.1128/aac.35.2.387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Rolston K. V., Ho D. H., LeBlanc B., Gooch G., Bodey G. P. Comparative in vitro activity of the new difluoro-quinolone temafloxacin (A-62254) against bacterial isolates from cancer patients. Eur J Clin Microbiol Infect Dis. 1988 Oct;7(5):684–686. doi: 10.1007/BF01964255. [DOI] [PubMed] [Google Scholar]
  25. Siegman-Igra Y., Bar-Yosef S., Gorea A., Avram J. Nosocomial acinetobacter meningitis secondary to invasive procedures: report of 25 cases and review. Clin Infect Dis. 1993 Nov;17(5):843–849. doi: 10.1093/clinids/17.5.843. [DOI] [PubMed] [Google Scholar]
  26. Sreedharan S., Peterson L. R., Fisher L. M. Ciprofloxacin resistance in coagulase-positive and -negative staphylococci: role of mutations at serine 84 in the DNA gyrase A protein of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother. 1991 Oct;35(10):2151–2154. doi: 10.1128/aac.35.10.2151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Tilley P. A., Roberts F. J. Bacteremia with Acinetobacter species: risk factors and prognosis in different clinical settings. Clin Infect Dis. 1994 Jun;18(6):896–900. doi: 10.1093/clinids/18.6.896. [DOI] [PubMed] [Google Scholar]
  28. Traub W. H., Spohr M. Antimicrobial drug susceptibility of clinical isolates of Acinetobacter species (A. baumannii, A. haemolyticus, genospecies 3, and genospecies 6). Antimicrob Agents Chemother. 1989 Sep;33(9):1617–1619. doi: 10.1128/aac.33.9.1617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Vila J., Almela M., Jimenez de Anta M. T. Laboratory investigation of hospital outbreak caused by two different multiresistant Acinetobacter calcoaceticus subsp. anitratus strains. J Clin Microbiol. 1989 May;27(5):1086–1089. doi: 10.1128/jcm.27.5.1086-1089.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Vila J., Marcos A., Marco F., Abdalla S., Vergara Y., Reig R., Gomez-Lus R., Jimenez de Anta T. In vitro antimicrobial production of beta-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother. 1993 Jan;37(1):138–141. doi: 10.1128/aac.37.1.138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Vila J., Ruiz J., Marco F., Barcelo A., Goñi P., Giralt E., Jimenez de Anta T. Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs. Antimicrob Agents Chemother. 1994 Oct;38(10):2477–2479. doi: 10.1128/aac.38.10.2477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Wang Y., Huang W. M., Taylor D. E. Cloning and nucleotide sequence of the Campylobacter jejuni gyrA gene and characterization of quinolone resistance mutations. Antimicrob Agents Chemother. 1993 Mar;37(3):457–463. doi: 10.1128/aac.37.3.457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Yoshida H., Bogaki M., Nakamura M., Nakamura S. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother. 1990 Jun;34(6):1271–1272. doi: 10.1128/aac.34.6.1271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Yoshida H., Bogaki M., Nakamura M., Yamanaka L. M., Nakamura S. Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother. 1991 Aug;35(8):1647–1650. doi: 10.1128/aac.35.8.1647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Yoshida H., Kojima T., Yamagishi J., Nakamura S. Quinolone-resistant mutations of the gyrA gene of Escherichia coli. Mol Gen Genet. 1988 Jan;211(1):1–7. doi: 10.1007/BF00338386. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES